Serotonin-sensitive adenylate cyclase activity of immature rat brain.
Cell-free preparations from superior and inferior colliculi of very young rats (1-3 days old) contained adenylate cyclase systems which were highly responsive to serotonin. The response to serotonin declined markedly during early development and was very low at maturity. Adenylate cyclase activity in the 10,000 times g particulate fraction from colliculi of newborn rats was significantly stimulated by 0.05 muM serotonin. Half-maximal activation was produced with less than 1 muM serotonin. Maximal stimulation of collicular adenylate cyclase was about 80% above basal enzyme activity and occurred with approximately 50 muM serotonin. Tryptamine and several derivatives of serotonin produced responses which were comparable to that obtained with serotonin; 5-methoxytryptamine was uniformly the most active compound tested. Norepinephrine or dopamine produced much smaller increases in adenylate cyclase activity. Stimulation of collicular adenylate cyclase by serotonin was significantly but incompletely blocked by serotonin antagonists, including d-lysergic acid diethylamide (d-LSD), 2-bromo-d-lysergic acid diethylamide, methysergide, 1-methyl-8 beta-carbobenzyloxy-aminomethyl-10 alpha-ergoline and cyproheptadine. Chlorpromazine also produced partial blockade. In contrast, l-lysergic acid diethylamide, haloperidol, propranolol, phenoxybenzamine and morphine were ineffective as serotonin blocking agents. Of the compounds which produced a partial blockage of serotonin action, d-LSD, cyproheptadine and chlorpromazine were themselves capable of stimulating adenylate cyclase activity. These results are consisent with the existence of multiple receptors in rat brain which are capable of interacting with indoleamines.
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D008735:5-Methoxytryptamine / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D000831:Animals, Newborn; D002474:Cell-Free System; D002746:Chlorpromazine / Q000494:pharmacology; D003533:Cyproheptadine / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D006220:Haloperidol / Q000494:pharmacology; D066298:In Vitro Techniques; D007245:Inferior Colliculi / Q000201:enzymology*; D008238:Lysergic Acid Diethylamide / Q000031:analogs & derivatives / Q000494:pharmacology; D008784:Methysergide / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D012701:Serotonin / Q000031:analogs & derivatives / Q000494:pharmacology*; D012702:Serotonin Antagonists; D013477:Superior Colliculi / Q000201:enzymology*; D014363:Tryptamines / Q000494:pharmacology
D012702:Serotonin Antagonists; D014363:Tryptamines; D010643:Phenoxybenzamine; D003533:Cyproheptadine; D012701:Serotonin; D008735:5-Methoxytryptamine; D009020:Morphine; D008238:Lysergic Acid Diethylamide; D011433:Propranolol; D006916:5-Hydroxytryptophan; D000262:Adenylyl Cyclases; D006220:Haloperidol; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine; D008784:Methysergide